drugset / Trial / NCT02542787
Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase II a Proof of concept study in Multiple Sclerosis (MS) patients with spasticity.
Timeline
- Start
- 2015-08
- Primary completion
- 2017-10
- Completion
- 2017-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VSN16R | Small molecule | 50 mg | Oral |
| Subject | VSN16R | Small molecule | 400 mg | Oral |